Allergy Therapeutics plc, the specialty pharmaceutical Company focused on allergy vaccination, announces today the successful completion and positive outcome of its key Phase II dose-ranging study, G203. The positive study results support the plan to take the Company’s lead product, Pollinex Quattro, into Phase III.
